Neuroleptic malignant syndrome: a study of CSF monoamine metabolism.
In 8 cases of typical neuroleptic malignant syndrome (NMS), homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA), noradrenaline (NA), and 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) levels in the cerebrospinal fluid (CSF) were assayed during both the active phase of NMS and after recovery. Compared with levels in normal control subjects the levels of HVA were significantly lower in patients with active NMS. This finding supports the central dopamine blockade theory of NMS pathophysiology. In addition, the levels of HVA were significantly decreased after recovery, suggesting that there may be a decreased dopamine metabolism in patients susceptible to NMS. The levels of 5-HIAA in patients with active NMS and after recovery were also significantly lower than those in normal control group, suggesting a relationship between the development of NMS and a disturbance of serotonin metabolism. The levels of NA in patients with active NMS were significantly higher than in normal subjects, and were within normal range after recovery. The levels of MHPG had a tendency to increase in patients with active NMS, compared with levels during recovery. These findings are a result of increased sympathetic nervous system activity in patients with active NMS; however, they are also observed in other disorders and may well reflect the physical stress caused by NMS.
Nisijima
K
K
Department of Psychiatry, Jichii Medical School, Tochigi-Ken, Japan.
Ishiguro
T
T
D000328:Adult; D015306:Biogenic Monoamines / Q000134:cerebrospinal fluid*; D001714:Bipolar Disorder / Q000134:cerebrospinal fluid; D003866:Depressive Disorder / Q000134:cerebrospinal fluid; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008607:Intellectual Disability / Q000134:cerebrospinal fluid; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000134:cerebrospinal fluid* / Q000175:diagnosis; D009638:Norepinephrine / Q000134:cerebrospinal fluid; D012559:Schizophrenia / Q000134:cerebrospinal fluid
D015306:Biogenic Monoamines; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D009638:Norepinephrine; D006719:Homovanillic Acid